Form 4: Karyopharm Therapeutics Executive Kristin Abate Sells Shares to Cover Tax Obligations

Kristin Abate, Chief Accounting Officer of Karyopharm Therapeutics, sold 571 shares of common stock on March 4, 2025, to cover withholding tax liabilities.

Summary

• Kristin Abate, the Chief Accounting Officer of Karyopharm Therapeutics Inc., sold 571 shares of the company's common stock on March 4, 2025.
• The sale was executed at a weighted average price of $6.29 per share, with individual transactions ranging from $6.12 to $6.31.
• The transaction was conducted under a pre-arranged automatic sale plan adopted on May 27, 2021, to cover withholding tax obligations related to the vesting of restricted stock units.
• Following the transaction, Abate directly owns 9,713 shares of Karyopharm Therapeutics Inc.
• The reporting person has undertaken to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer.

Sentiment

Score: 5

Explanation: The document describes a routine stock sale by an executive to cover tax obligations, which is neither particularly positive nor negative.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to have a significant effect given the context of tax obligations and the pre-arranged sale plan.

Key Dates

Keywords

Karyopharm Therapeutics, Kristin Abate, stock sale, Form 4, insider trading, Chief Accounting Officer, automatic sale plan, withholding tax, restricted stock units